Literature DB >> 24599923

Pulmonary hypertension in systemic lupus erythematosus: echocardiography-based definitions predict 6-year survival.

Claudia Hübbe-Tena1, Selma Gallegos-Nava1, Ricardo Márquez-Velasco1, Diana Castillo-Martínez1, Jesus Vargas-Barrón2, Julio Sandoval2, Luis M Amezcua-Guerra3.   

Abstract

OBJECTIVE: The aim of this study was to investigate whether a core of echocardiography-based definitions of pulmonary hypertension (PH), as proposed by the European Society of Cardiology, European Respiratory Society and International Society of Heart and Lung Transplantation (ESC/ERS/ISHLT), may predict long-term survival in patients with SLE.
METHODS: A post hoc analysis from a cohort of SLE patients followed over 6 years was performed. Clinical associations, serum biomarkers, autoantibody profile, length of survival and all-cause mortality were assessed.
RESULTS: Out of 115 patients from the original cohort, 55 satisfied our inclusion criteria and were grouped according to echocardiography as unlikely (n = 26), possible (n = 16) or likely (n = 13) to have PH. Likely PH was associated with a history of pulmonary thromboembolism, higher cumulated organ damage and active arthritis. The 6-year survival rate was 88% in the unlikely PH group, 87% in the possible PH group and 68% in the likely PH group (P < 0.05). Serum levels of endothelin-1, monocyte chemotactic protein-1, IL-17, and IFN-γ as well as a number of autoantibodies were no different between groups.
CONCLUSION: The ESC/ERS/ISHLT echocardiography-based definitions of PH are useful to predict 6-year mortality in SLE patients. A history of pulmonary thromboembolism and lung vasculitis/haemorrhage, cumulated organ damage and long-lasting disease are associated with PH in SLE.
© The Author 2014. Published by Oxford University Press on behalf of the British Society for Rheumatology. All rights reserved. For Permissions, please email: journals.permissions@oup.com.

Entities:  

Keywords:  MCP-1; echocardiography; endothelin-1; pulmonary hypertension; survival; systemic lupus erythematosus

Mesh:

Year:  2014        PMID: 24599923     DOI: 10.1093/rheumatology/keu012

Source DB:  PubMed          Journal:  Rheumatology (Oxford)        ISSN: 1462-0324            Impact factor:   7.580


  4 in total

Review 1.  Pulmonary hypertension in antiphospholipid syndrome.

Authors:  Stéphane Zuily; Denis Wahl
Journal:  Curr Rheumatol Rep       Date:  2015-01       Impact factor: 4.592

Review 2.  "How many times must a man look up before he can really see the sky?" Rheumatic cardiovascular disease in the era of multimodality imaging.

Authors:  Sophie I Mavrogeni; George Markousis-Mavrogenis; David Heutemann; Kees van Wijk; Hans J Reiber; Genovefa Kolovou
Journal:  World J Methodol       Date:  2015-09-26

3.  Pulmonary arterial hemodynamic assessment by a novel index in systemic lupus erythematosus patients: pulmonary pulse transit time.

Authors:  Tolga Han Efe; Mehmet Doğan; Cem Özişler; Tolga Çimen; Mehmet Ali Felekoğlu; Ahmet Göktuğ Ertem; Engin Algül; Sadık Açıkel
Journal:  Anatol J Cardiol       Date:  2017-06-22       Impact factor: 1.596

4.  Outcomes and Risk Factors of Systolic Pulmonary Artery Pressure Progression in Patients with Systemic Rheumatic Diseases: Follow-up Results from a Korean Registry.

Authors:  Mi Ryoung Seo; Jina Yeo; Hee Jung Ryu; Hyo-Jin Choi; Kwang-Pil Ko; Han Joo Baek
Journal:  Arch Rheumatol       Date:  2020-04-27       Impact factor: 1.472

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.